Repligen Corporation (NASDAQ: RGEN) and Assembly Biosciences (NASDAQ:ASMB) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
Valuation and Earnings
This table compares Repligen Corporation and Assembly Biosciences’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Repligen Corporation||$113.32 million||12.69||$29.54 million||$0.51||75.49|
|Assembly Biosciences||$3.04 million||191.35||-$50.92 million||($2.93)||-11.43|
Repligen Corporation has higher revenue and earnings than Assembly Biosciences. Assembly Biosciences is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.
This table compares Repligen Corporation and Assembly Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility and Risk
Repligen Corporation has a beta of 1.18, indicating that its share price is 18% more volatile than the S&P 500. Comparatively, Assembly Biosciences has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Insider and Institutional Ownership
97.9% of Repligen Corporation shares are owned by institutional investors. Comparatively, 72.3% of Assembly Biosciences shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by insiders. Comparatively, 19.6% of Assembly Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a summary of recent ratings and recommmendations for Repligen Corporation and Assembly Biosciences, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Repligen Corporation currently has a consensus target price of $46.00, suggesting a potential upside of 19.48%. Assembly Biosciences has a consensus target price of $35.00, suggesting a potential upside of 4.48%. Given Repligen Corporation’s higher probable upside, analysts plainly believe Repligen Corporation is more favorable than Assembly Biosciences.
Repligen Corporation beats Assembly Biosciences on 10 of the 13 factors compared between the two stocks.
Repligen Corporation Company Profile
Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.
Assembly Biosciences Company Profile
Assembly Biosciences, Inc. is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome. It has discovered various core protein Allosteric Modulators (CpAMs), which are small molecules that directly target and allosterically modulate the HBV core (HBc) protein. Its Microbiome Program consists of an integrated platform that includes a strain identification and selection process, methods for strain isolation and growth under current good manufacturing practice conditions, and a delivery system, GEMICEL, which allows for targeted oral delivery of live biologic and conventional therapies to the lower gastrointestinal (GI) tract. The lead product candidate from this platform, AB-M101, is in development for the treatment of clostridium difficile-infections.
Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with MarketBeat.com's FREE daily email newsletter.